Creative Medical Technology Holdings announced the launch of its BioDefense Inc. Veterans Initiative, a national program designed to address the long‑term health effects of burn pit exposure among U.S. service members.
The initiative will leverage the company’s proprietary induced pluripotent stem cell (iPSC) platform and AI‑driven analytics to build a comprehensive molecular database of burn‑pit‑related injuries, with the goal of developing precision regenerative countermeasures for respiratory, cardiovascular, and neurological damage.
Greenstone Biosciences will provide advanced sequencing, proteomic profiling, and machine‑learning models to accelerate therapy development. The partnership builds on a collaboration that began in June 2022 and positions Creative Medical as a key player in national biodefense.
Creative Medical has historically reported net losses and minimal revenue, but recently raised $4.2 million through warrant exercises. The company’s focus on regenerative medicine and biodefense aligns with the PACT Act of 2022, which expanded benefits for veterans exposed to burn pits. The initiative represents a strategic expansion beyond its core regenerative pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.